MaxCyte, Inc.
MXCT US
MXCT USMaxCyte, Inc.
United States Composite3.83
Company Description
- CEO
- Mr. Maher Masoud
- Full Time Employees
- 143
- Sector
- Healthcare
- Industry
- Medical Devices
- Address
- 9713 Key West Avenue Rockville MD United States 20850
- IPO Date
- Mar 29, 2016
- Website
- www.maxcyte.com
- Business
- MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Company News
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results